Loading articles…
Loading articles…
Research included in this condition report
12 rights-cleared articles published in 2026, ordered newest first.
12 articles from 2026
Newest firstBackground Patients with inflammatory bowel disease (IBD) increasingly use cannabis. Studies investigating the effectiveness and safety of cannabis as a therapeutic option for IBD have reported conflicting findings, and recent reviews have not incorporated evidence from real-world studies. This systematic review assessed controlled non-interventional studies and interventional trials evaluating the effectiveness o…
Background Inflammatory bowel disease (IBD) is a broad classification including various chronic inflammatory gastrointestinal conditions that comprises two main disorders: Crohn's disease (CD) and ulcerative colitis (UC). The key components of the endocannabinoid system (ECS) are highly expressed within the gastrointestinal tract, playing a crucial role in maintaining homeostasis and providing protection against i…
The endocannabinoid system (ECS) is increasingly recognized as a central regulator of immune homeostasis, integrating neural, metabolic, and immune signaling to maintain physiological equilibrium. This Perspective examines the “therapeutic paradox” of endocannabinoid immunomodulation, whereby anti-inflammatory and tissue-protective effects are mechanistically linked to transient immunosuppression. Although cannabi…
BACKGROUND: Inflammatory bowel diseases (IBD) are often associated with intestinal fibrosis. There is increased interest in new methods for managing intestinal fibrosis, among which the endocannabinoid system (ECS) is an interesting therapeutic target. The primary purpose of the study was to evaluate the effect of CB1/2 agonist, WIN 55,212-2 (WIN) on expression of fibrosis regulatory proteins: alpha smooth muscle…
BACKGROUND: Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of the digestive tract. Mucositis and IBD/colitis are characterized by weight loss and intestinal inflammation. Previous animal studies suggest that the cannabinoid, ∆9-tetrahydrocannabinol (THC), attenuates intestinal inflammation. We aimed to invest…
AbstractBackgroundIndividuals with inflammatory bowel disease (IBD) experience mental health disorders at rates 1.5-2 times higher than the general population. Many are affected during major life stages such as pregnancy, yet data on how IBD influences anxiety and depression in pregnancy remain limited.MethodsThis retrospective survey study included patients from the “Preconception and Pregnancy in IBD” clinic who…
The gut microbiota constitutes a metabolically active ecosystem that dynamically interacts with the host lipid metabolism and cellular signaling networks. While dietary lipids shape the microbial composition and metabolite production, the microbiota reciprocally biotransform fatty acids, thereby regulating lipid mediator bioavailability and host cellular responses. This bidirectional molecular crosstalk plays a pi…
Leukocyte trafficking is a critical step in the development of chronic intestinal diseases such as Crohn's disease. While strategies that block gut homing have yielded partial success, this disease remains uncurable leaving an unmet clinical need. This is the first paper to describe a role for cannabinoid receptor 2 (CB2R) signaling in promoting retinoic acid-mediated induction of the gut homing associated integri…
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation, epithelial barrier disruption, and immune dysregulation. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, and sodium propionate (Na-P), a short-chain fatty acid, posses complementary anti-inflammatory and epithelial-protective properties. This study aimed to evaluate the safety and efficacy of…
Cannabidiol (CBD) is increasingly used for symptom relief in chronic conditions, yet its role in inflammatory bowel disease (IBD) remains underexplored. We surveyed 229 IBD patients and found that 10.5% used CBD, primarily for anxiety (54.2%), insomnia (41.7%), and pain (41.7%). Among users, 87.5% perceived benefit. Most users were female, and one-third were on biologics. These findings highlight the growing inter…
BackgroundUnplanned hospital admissions in Inflammatory Bowel Diseases (IBD) account for nearly three-quarters of IBD inpatient stays in the United Kingdom. Although costly to services and distressing for patients, research exploring experiences and potential drivers of admissions is limited. We undertook a qualitative study to explore the healthcare experiences and access needs of people with IBD who had unplanne…
BackgroundAccess to healthcare may be driving unplanned and potentially avoidable hospital admissions for people diagnosed with Inflammatory Bowel Disease (IBD). Interventions to reduce unplanned and potentially avoidable admissions need to be developed based on a clear conceptual framework that identifies the system-level access barriers contributing to these admissions. This scoping review aimed to synthesise th…